期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物标志物检测技术在指导食管癌新辅助治疗中的应用

Applications of the biomaker-detection technology guiding neoadjuvant therapy for advanced esophageal cancer
原文传递
导出
摘要 目前，运用生物标志物预测食管癌新辅助治疗疗效技术已广泛应用于临床。生物标志物检测途径众多，主要包括免疫组织化学检测、血清标志物检测和常规血液检查等传统检测技术，以及基因表达谱分析、单核苷酸多态性分析、miRNA检测、蛋白质组学分析等新兴技术。随着生物技术的发展，牛物标志物检测技术有望成为评估食管癌新辅助治疗疗效、风险、预后以及选择个体化治疗方案的有效下段。 At present, the technology to predict the response to neoadjuvant therapy with biomakers has been widely used in clinical practice. The approaches of biomarkers detection are various, including immuno- histochemistry, detection of serum biomarkers conventional blood tests, gene expression profile analysis, single nucleotide polymorphisms, miRNAs, proteomics analysis. With the development of biotechnology, the techno- logy of biomarkers detection is expected to become effective means in assessment of adjuvant therapy, risk, prognosis and individualization in esophageal cancer treatment.
作者 李晨 程玉峰
机构地区 山东大学齐鲁医院放疗科
出处 《国际肿瘤学杂志》 CAS 2015年第12期924-927,共4页 Journal of International Oncology
关键词 食管肿瘤 生物学标记 肿瘤辅助疗法 Esophageal neoplasms Biological makers Neoadjuvant therapy
分类号 R735.1 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Bollschweiler E, Hlscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer[J].Future Oncol.2010, 6(1):25-35.
  • 2Nguyen NP, Krafft SP, VinhHung V, et al. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to threedimensional radiotherapy[J].Radiother Oncol.2011, 101(3):438-442.
  • 3Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival[J].J Clin Oncol.2005, 23(19):4330-4337.
  • 4吕雅蕾,刘巍,左静,王玉栋,刘晓,冯莉,荆丽.ERCC1、ERCC2与食管癌临床病理特征和预后关系的研究[J].临床肿瘤学杂志,2010,15(7):600-604. 被引量：9
  • 5Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin[J].Ann Surg Oncol.2012, 19(3):757-765.
  • 6Vallbhmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer[J].Dis Esophagus.2006, 19(6):425-432.
  • 7Yasunaga M, Tabira Y, Nakano K, et al. Accelerated growth signals and low tumorinfiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma[J].Ann Thorac Surg.2000, 70(5):1634-1640.
  • 8郑成义,王朝阳,闻吉军,庄成全.食管鳞癌中NF-κB、p53的表达及其与新辅助化疗敏感性的关系[J].现代肿瘤医学,2009,17(12):2328-2330. 被引量：6
  • 9Brabender J, Metzger R, Vallbhmer D, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer[J].Surgery.2012, 151(2):306-312.
  • 10Makuuchi Y, Honda K, Osaka Y, et al. Soluble interleukin6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy[J].Cancer Sci.2013, 104(8):1045-1051.

二级参考文献21

  • 1肖宁新,李仲宏,金亦,王国强,苏祖兰.乳腺癌组织p21^(WAF1)基因多态性与蛋白表达的关系[J].中国病理生理杂志,2004,20(6):976-980. 被引量：2
  • 2许凯黎,陈惠黎.肿瘤标志物,/汤钊猷.现代肿瘤学.2版.上海:上海出版社,2000:345-366.
  • 3Wakatsuki M, Suzuki Y, Nakamoto S, et al. Clinical usefulness of CYFRA21-1 for esophageal squamous cell carcinoma in radiation therapy. Gastroenterol Hepatol, 2007, 22:715-719.
  • 4Shimada H, Nabeya Y, Okazumi S, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinbma. Surgery, 2003, 133: 486-494.
  • 5Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA21-1 determination in patients with esophageal squamous cell carcinoma : clinical utility for detection of recurrences. Cancer, 2000, 89: 1413-1417.
  • 6Brockmann JG, St Nottberg H, Glodny B, et al. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer. Anticancer Res, 2000, 20:4.899-4904.
  • 7Brockmann J G, St Nottberg H, Glodny B, et al. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res, 2000, 6: 4249-4252.
  • 8Wachters FM, Wong LS, Timens W, et al. ERCC1, hRad51,and BRCAI protein exp rcssion in relation to turnout response andsurvival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy[J]. Lung Cancer, 2005, 50(2): 211 -219.
  • 9Nishina T, Matsubara J, Toshikazu M, et al. Clinical significance of dihydropyrimidine dehydrogenase ( DPD ) , epidermal growth factor receptor( EGFR), and excision repair cross-complementing gene 1 ( ERCC1 ) gene expression of tumor tissue in patients with advanced gastric cancer[ J]. J Clin Oncol, 2007,25 ( 18 Suppl) :a4629.
  • 10Rosell R, Jassem E, Skrzypski M, et al. Increased BRCA1 mRNA: An independent prognostic variable in completely resected chemo-naive non-small cell lung cancer(NSCLC) patients (p) [J]. JCO, 2007, 25(18 Suppl): a7551.

共引文献14

国际肿瘤学杂志
2015年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部